Boston University Libraries OpenBU
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    •   OpenBU
    • Theses & Dissertations
    • Boston University Theses & Dissertations
    • View Item
    •   OpenBU
    • Theses & Dissertations
    • Boston University Theses & Dissertations
    • View Item

    Current state of precision therapy for the management of lung adenocarcinoma

    Thumbnail
    Date Issued
    2019
    Author(s)
    Sykora, Chelsea
    Share to FacebookShare to TwitterShare by Email
    Export Citation
    Download to BibTex
    Download to EndNote/RefMan (RIS)
    Metadata
    Show full item record
    Permanent Link
    https://hdl.handle.net/2144/36610
    Abstract
    Lung adenocarcinoma (LUAD) is a subtype of non small-cell lung cancer that has been characterized by late stage diagnosis and poor clinical outcomes. Recent advances in tumor genotyping and precision therapies have shifted the landscape of LUAD management, drastically improving outcomes for a large subset of patients. Specific tyrosine kinase inhibitors have been developed to target oncogenic aberrations harbored by different molecular subtypes of LUAD. Although many of these targeted therapies have proven to be more efficacious than traditional chemotherapy, the constant battle against acquired resistance has limited their success. This has warranted the development of second- and third-generation tyrosine kinase inhibitors, chronically directed at more and more specific targets. This review focuses on the eight most frequent LUAD oncogenic drivers and the effectiveness of their associated targeted therapies. The goal of this thesis is to evaluate each molecular target as a candidate for precision medicine, identify targeted therapies which hold the most promise, and characterize the current state of LUAD precision therapy. By comparing progression free survival rates, safety profiles, and resistance data for each genetic aberration, it was concluded that epidermal growth factor receptor (EGFR) and ROS proto-oncogene 1 (ROS1) directed therapies hold the most promise for improving clinical outcomes for EGFR mutant-positive and ROS1 fusion-positive patient populations. Though curative options will likely not be seen in the near future, the progress made by precision medicine is encouraging. By focusing further research on elucidating resistance mechanisms, identifying novel oncogenic drivers, and trialing combination therapies, patient outcomes can continue to improve.
    Collections
    • Boston University Theses & Dissertations [6787]


    Boston University
    Contact Us | Send Feedback | Help
     

     

    Browse

    All of OpenBUCommunities & CollectionsIssue DateAuthorsTitlesSubjectsThis CollectionIssue DateAuthorsTitlesSubjects

    Deposit Materials

    LoginNon-BU Registration

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Boston University
    Contact Us | Send Feedback | Help